ArticleInternational journal of nanomedicine2026
Carbon Dots Derived from
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute kidney injury (AKI) is a severe clinical condition with high morbidity and mortality that lacks effective therapies. Carbon dots (CDs) derived from traditional Chinese medicine ingredients have emerged as promising therapeutic agents because of their favorable biosafety profile and potent antioxidant and anti-inflammatory properties. In this study, the therapeutic effects of CDs derived from Methods: LC-CDs were developed through a facile hydrothermal method and were used to treat an ischemia-reperfusion AKI rat model and HK-2 cells with hypoxia/reoxygenation injury. Results: LC-CDs with uniform nanostructures, graphitic carbon structures, and multiple chemical functional groups on the surface were successfully synthesized. The LC-CDs exhibited excellent hydrophilicity, chemical reactivity, and unique optical properties. Treatment with the LC-CDs significantly reduced creatinine and blood urea nitrogen levels and alleviated pathological damage in renal tissue. Additionally, the LC-CDs effectively cleared reactive oxygen species, reduced oxidative stress levels, and mitigated mitochondrial damage. Treatment with the LC-CDs also decreased renal tissue expression of key inflammatory factors (IL-1β, IL-6, and TNF-α). Transcriptome analysis revealed that differentially expressed genes associated with the LC‑CDs were primarily involved in the autophagy, and inflammatory signaling pathways. Further subcellular fractionation and fluorescence localization analyses confirmed that the LC-CDs accumulated in and targeted mitochondria, suggesting that mitochondria are the primary organelle target through which the LC-CDs exert their effects. Autophagy-related signaling pathways likely also played a critical role in mediating the therapeutic efficacy of the LC-CDs. Conclusion: The LC-CDs demonstrated considerable therapeutic potential in an AKI model through their antioxidant, anti-inflammatory, and autophagy regulation. Their outstanding biocompatibility, multifunctional synergistic properties, and well-defined molecular targets provide a crucial foundation for the development of novel nanomedicines and kidney-targeted delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.